These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 18154548)

  • 1. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS; García JA; Muñoz JL
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from a university hospital in south-western Germany.
    Wienke M; Pfeifer Y; Weissgerber P; Marschal M; Autenrieth IB; Gröbner S
    Chemotherapy; 2012; 58(3):241-8. PubMed ID: 22832033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).
    Hirakata Y; Matsuda J; Miyazaki Y; Kamihira S; Kawakami S; Miyazawa Y; Ono Y; Nakazaki N; Hirata Y; Inoue M; Turnidge JD; Bell JM; Jones RN; Kohno S;
    Diagn Microbiol Infect Dis; 2005 Aug; 52(4):323-9. PubMed ID: 16165001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
    Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
    Livermore DM; Hope R; Mushtaq S; Warner M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR; Dowzicky MJ
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Hoban DJ; Bouchillon SK; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):423-8. PubMed ID: 17403448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.